Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
- PMID: 7730348
- DOI: 10.1074/jbc.270.17.9709
Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells
Abstract
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and endothelial cell-specific mitogen that stimulates urokinase-type plasminogen activator (uPA) activity in vascular endothelial cells. Here, we report that VEGF increases the high affinity binding of uPA to the same cells and that this binding is prevented by a peptide corresponding to the uPA receptor (uPAR) binding growth factor-like domain of uPA. Ligand cross-linking, ligand blotting, and uPA-Sepharose affinity chromatography revealed an increase in a cell surface uPA binding protein that corresponds to the uPAR on the basis of its affinity for uPA, M(r) of 50,000-55,000, and phosphatidylinositol-specific phospholipase C sensitivity. By Scatchard analysis, VEGF increased the number of uPAR molecules by 2.8-3.5-fold and concomitantly decreased their affinity for uPA. By northern blotting uPAR mRNA was increased in a dose- and time-dependent manner in response to VEGF. Taken together, these findings demonstrate that VEGF-induced angiogenesis is accompanied by increased uPAR expression and uPA activity on the endothelial cell surface. These observations are consistent with the notion that the uPA-uPAR interaction facilitates cellular invasion.
Similar articles
-
VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor.FASEB J. 2003 Apr;17(6):752-4. doi: 10.1096/fj.02-0484fje. Epub 2003 Feb 19. FASEB J. 2003. PMID: 12594181
-
Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix.Blood. 2000 Oct 15;96(8):2775-83. Blood. 2000. PMID: 11023511
-
Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.J Cell Physiol. 1996 Nov;169(2):300-8. doi: 10.1002/(SICI)1097-4652(199611)169:2<300::AID-JCP9>3.0.CO;2-S. J Cell Physiol. 1996. PMID: 8908197
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
-
Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells.EXS. 1997;79:391-411. doi: 10.1007/978-3-0348-9006-9_16. EXS. 1997. PMID: 9002228 Review.
Cited by
-
Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.Clin Exp Metastasis. 2009;26(7):653-61. doi: 10.1007/s10585-009-9264-9. Epub 2009 May 15. Clin Exp Metastasis. 2009. PMID: 19444623
-
Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis.Cancer Metastasis Rev. 1996 Jun;15(2):165-76. doi: 10.1007/BF00437469. Cancer Metastasis Rev. 1996. PMID: 8842488 Review.
-
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.Clin Exp Metastasis. 1998 Jan;16(1):9-20. doi: 10.1023/a:1006503816792. Clin Exp Metastasis. 1998. PMID: 9502073
-
Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.Cell Mol Life Sci. 2016 Apr;73(7):1333-48. doi: 10.1007/s00018-015-2098-5. Epub 2015 Dec 1. Cell Mol Life Sci. 2016. PMID: 26626411 Free PMC article. Review.
-
Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.Neurol Med Chir (Tokyo). 2013;53(11):755-63. doi: 10.2176/nmc.ra2013-0200. Epub 2013 Oct 25. Neurol Med Chir (Tokyo). 2013. PMID: 24162241 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous